Sponsored
As IRA price negotiations reshape the pharmaceutical landscape, leading policy experts unpack what executives need to know now to navigate pricing uncertainty, biosimilar competition, and long-term strategic risk.
Kirsten Axelsen, DLA Piper
Advertisement
Articles by Kirsten Axelsen, DLA Piper
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Launch is Just the Beginning: Rare Disease Care Requires Durability
2
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
3
Novartis to Layoff 322 NJ Employees: Report
4
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
5